Longeveron Seeks Shareholder Approval for Reverse Split, Massive Authorized Share Increase, and Expanded Equity Plan
LGVN sits 64% above its 52-week low of $0.475 on light trading volume (0.1× avg).
Summary
Longeveron is asking shareholders to approve a reverse stock split, a massive increase in authorized shares to 175 million, and an expansion of its equity incentive plan, signaling potential for extreme future dilution amidst financial distress.
Key Events · Corporate Governance and Compliance · LGVN
-
Reverse Stock Split Proposal
Shareholders will vote on a reverse stock split (1:2 to 1:20) to help the company regain Nasdaq compliance, following a preliminary proxy filing on May 5, 2026.
-
Massive Authorized Share Increase
The company seeks to increase authorized Class A common stock to 175,000,000 shares, enabling substantial future capital raises or other dilutive actions. This represents a significant potential for dilution given the current outstanding share count.
-
Expanded Equity Incentive Plan
An additional 5,000,000 shares are proposed for the 2021 Incentive Award Plan, further increasing potential dilution for existing shareholders.
-
Shareholder Meeting Scheduled
The annual meeting is set for July 1, 2026, where these critical proposals will be voted upon.
Analysis · LGVN · Life Sciences
Longeveron Inc. is seeking shareholder approval for several critical proposals at its upcoming July 1, 2026 meeting. These include a reverse stock split (1:2 to 1:20) to maintain its Nasdaq listing, a substantial increase in authorized Class A common stock to 175 million shares, and an additional 5 million shares for its equity incentive plan. These proposals, particularly the massive increase in authorized shares, set the stage for significant future dilution, which is a major concern given the company's ongoing "going concern" issues, recent deeply discounted private placement, and a major regulatory setback for its lead drug candidate.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 45.8% of the 251 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.67%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LGVN was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.4M. The 52-week trading range was $0.48 to $1.80. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.